Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.

Doctor looking at total hip replacement X-ray film with blurred hospital background

Conducted by the Oxford Clinical Trials Research Unit (OCTRU), and published in The Bone and Joint Journal, the trial compared the effectiveness of two different implants used to treat broken hips but found no clinically relevant difference between treatments.

The sliding hip screw (SHS) is a well-established treatment for hip fractures. A screw and plate is inserted into the thigh bone around the hip joint to hold the hip in place, leading to successful bone healing. However, in some patients, osteoporosis weakens the bones meaning they are not strong enough for the screw to hold in place. The broken bones can then come apart leaving some patients needing a second operation.

A new type of implant, the X-Bolt (XHS), was tested against the SHS to see if it was more effective. The X-Bolt builds on the successful design features of the SHS, the main difference being a bolt that expands within the femoral head, compressing the surrounding bone to improve fixation.

The trial recruited 1128 people, aged 60+ years who were being treated for a hip fracture. Participants were randomised into two groups, with half treated with the SHS implant, the other half with the X-Bolt. The primary outcome measure was health-related quality of life (HRQoL) measured at four months, collected through patient questionnaires and review of the medical records.  

The trial found that any difference in four-month health-related quality of life between the two implants was small and probably not clinically important.  The risk of needing a second operation was approximately 3% in both groups.

Professor Xavier Griffin, who led the research said: “The two implants perform equally well in terms of patient outcomes. The revision surgery risk was low in both arms indicating that the UK treatment systems are working well. We concluded that surgeons should choose the implant that they are most familiar with or prefer to use.”

Hip fractures remain a huge challenge for the medical community and are the most common injury in older people that requires treatment in hospital. There were an estimated nine million osteoporotic fractures globally in 2000, of which 1.6 million were hip fractures. With aging populations these figures are set to increase. The socioeconomic cost is estimated at 5.8 million disability adjusted life years lost and represents 1.75% of the total healthcare burden in established market economies.

The study was funded by X-Bolt Ltd and was supported by the National Institute for Health Research Oxford Biomedical Research Centre. 

WHiTE 4 Subtitles from Duncan Appelbe on Vimeo.

Similar stories

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.